HDAC9 and ovarian cancer: Most interestingly, SCFA have been demonstrated to play a role in inhibiting HDAC in ovarian cancer cells lines and it has been suggested that combining valproic acid with chemotherapeutics such as paclitaxel or doxorubicin could result in increased apoptosis, decreased poly (ADP-ribose) polymerase enzymes, and inhibition of DNA repair in ovarian cancer cells, although yet to be tested clinically [90].